You have 9 free searches left this month | for more free features.

Lymphoma

Showing 1 - 25 of 9,106

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)

Not yet recruiting
  • Lymphoma, Non-Hodgkin Lymphoma, B-Cell
  • BAFF CAR-T
  • (no location specified)
Aug 16, 2022

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Mar 16, 2022

Lymphoma Trial (Tislelizumab)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 28, 2022

Living Conditions After Non-Hodgkin's Lymphoma in France

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Data collection
  • Questionnaires
  • Dijon, France
    Chu Dijon Bourgogne
Oct 13, 2022

Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Buparlisib, Ibrutinib)

Active, not recruiting
  • Lymphoma
  • +3 more
  • Basking Ridge, New Jersey
  • +5 more
Jun 13, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 20, 2022

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

PET/CT Vs Bone Marrow Biopsy in Exclusion of Bone Marrow

Not yet recruiting
  • Lymphoma
  • positron emission tomography for exclusion of bone marrow infiltration in lymphoma
  • (no location specified)
Oct 28, 2022

B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma Trial in Pittsburgh (Chimeric Antigen Receptor

Recruiting
  • B-Cell Lymphoma
  • +8 more
  • Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
  • Pittsburgh, Pennsylvania
    AHN Cancer Institute - West Penn Hospital
Aug 10, 2022

Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

Recruiting
  • Recurrent Angioimmunoblastic T-Cell Lymphoma
  • +13 more
  • Brentuximab Vedotin
  • Pembrolizumab
  • Chicago, Illinois
    Northwestern University
Jun 15, 2022

Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell Trial in New York (Pharmacokinetics)

Recruiting
  • Lymphoma
  • +4 more
  • Pharmacokinetics
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Sep 12, 2022

Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)

Completed
  • Burkitt's Lymphoma
  • +4 more
  • Frankfurt, Germany
    University Hospital, Medical Dept. II
Aug 17, 2022

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Palo Alto (Ibrutinib, Radiation

Active, not recruiting
  • Grade 1 Follicular Lymphoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Jun 13, 2022

Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma Trial in Hangzhou (RD14-01 cell infusion)

Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • RD14-01 cell infusion
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Jul 6, 2022

A Study of People With CD30 Positive Lymphoma in China

Not yet recruiting
  • Lymphoma
    • (no location specified)
    Aug 17, 2022

    Cardiovascular Events Among Adults Relapsed or Refractory

    Recruiting
    • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
    • +9 more
    • Electronic Health Record Review
    • Houston, Texas
      M D Anderson Cancer Center
    May 24, 2022

    Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

    Active, not recruiting
    • Anaplastic Large Cell Lymphoma
    • +4 more
    • Duarte, California
    • +3 more
    Jul 21, 2022

    Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

    Recruiting
    • Lymphoma
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 20, 2022

    NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

    Not yet recruiting
    • NK/T Cell Lymphoma
    • +2 more
    • Guangzhou, Guangdong, China
    • +1 more
    Jan 12, 2023

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022

    Lymphoma, Survivorship Trial in Boston (Interview with Clinicians, Field Test of UPLYFT with Lymphoma Survivors, Pilot of UPLYFT

    Recruiting
    • Lymphoma
    • Survivorship
    • Interview with Clinicians
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 14, 2022

    Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)

    Not yet recruiting
    • Lymphoma, Mantle-Cell
    • +7 more
    • (no location specified)
    Jun 21, 2022

    T Lymphoblastic Leukemia/Lymphoma Trial in Shenzhen (CD7 CAR-T cells)

    Recruiting
    • T Lymphoblastic Leukemia/Lymphoma
    • CD7 CAR-T cells
    • Shenzhen, Guangdong, China
      Li Yu
    Nov 11, 2022